SCHEMBL3015091

SCHEMBL3015091

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4c(C)c(C)cc(C)c4C)CC3)n2)cc1C

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DNM1L O00429 19/20 0.35
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015170 0.91 SMN1; SMN2 (0.38) DNM1LHRH3
SCHEMBL3018899 0.90 LMNA (0.39) DNM1LHRH3
SCHEMBL3009050 0.90 DNM1L (0.35) DNM1LHRH3
SCHEMBL3016255 0.90 DNM1L (0.35) DNM1LHRH3
SCHEMBL3008623 0.90 CACNA1G (0.36) DNM1LHRH3
SCHEMBL3008645 0.89 MAPT (0.37) DNM1LHRH3
SCHEMBL3012509 0.89 DNM1L (0.34) DNM1LHRH3
SCHEMBL2998099 0.89 DNM1L (0.42) DNM1L
SCHEMBL3006205 0.89 DNM1L (0.39) DNM1L
SCHEMBL3016708 0.89 DNM1L (0.35) DNM1LHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA DNM1L 180/4885HRH3 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.